Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene test could predict kidney cancer in transplant patients

NCT ID NCT03114826

Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study examined whether a specific variation in the VEGF gene (rs699947) is linked to a higher risk of developing kidney cancer in people who have received a kidney transplant. Researchers analyzed DNA from 272 transplant patients, some of whom had kidney cancer. The goal was to see if this genetic marker could help identify high-risk patients and guide safer immunosuppressant choices.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors choose safer immunosuppressants for kidney transplant patients at higher genetic risk of kidney cancer.
What could go wrong
This is an observational study, not a treatment trial. It only looks for a link between a gene variant and cancer risk, so it cannot prove cause or change care directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

272 people

The number who actually took part.

Started

Oct 2016

Finished

Dec 2018

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Renal transplant patients for the period 1 January 2002 to 31 December 2011

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving a first, second or third kidney transplant; * Patients receiving a transplant from a living or deceased donor, irrespective of the immunological risk; * Patients with health insurance coverage; * Live or deceased patients for which genomic DNA is available. * in cases : first diagnosis of native kidney cancer (histological type: papillary or clear cell) Exclusion Criteria: * Minor transplant patients; * Patients transplanted before 1 January 2002; * Patients monitored in the interregion, but transplanted to another center; * Patients receiving a double graft (kidney plus other organ) or a bi-graft; * Patients not accepting that their medical data be included in the register; * Patients not accepting that their specimen be used for scientific research purposes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Polymorphism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Polymorphism Renal carcinoma Renal transplantation VEGF

Contacts and locations

Locations

  • CHU Amiens Picardie

    Amiens, Picardie, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.